Nykode Therapeutics ASA Logo

Nykode Therapeutics ASA

Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.

NYKD | OL

Overview

Corporate Details

ISIN(s):
NO0010714785
LEI:
254900UKQHWYZJD22017
Country:
Norway
Address:
Gaustadalleen 21, 0349 Oslo
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies and vaccines. The company's core is its innovative, modular technology platform centered on the proprietary Vaccibody™ molecule. This platform is engineered to deliver antigens with tailored hyper-targeting to Antigen Presenting Cells, inducing rapid, robust, and long-lasting immune responses. Nykode's approach demonstrates a positive safety profile and has the potential to treat and prevent a wide range of diseases, with a significant focus on cancer.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-27 07:01
Regulatory News Service
Nykode Announces Updated Strategy to Increase Value for Patients and Shareholde…
English 176.0 KB
2025-08-27 07:01
Regulatory News Service
Nykode Announces Updated Strategy to Increase Value for Patients and Shareholde…
English 12.9 KB
2025-08-27 07:00
Interim Report
Nykode Therapeutics - Quarterly report Q2 2025 - Attachment: 250827 Nykode Quar…
English 11.4 MB
2025-08-27 07:00
Report Publication Announcement
Nykode Therapeutics - Quarterly report Q2 2025
English 3.0 KB
2025-08-20 08:00
Report Publication Announcement
Nykode Therapeutics – Invitation to Q2 2025 Financial Results Presentation and …
English 125.6 KB
2025-08-20 08:00
Report Publication Announcement
Nykode Therapeutics – Invitation to Q2 2025 Financial Results Presentation and …
English 3.3 KB
2025-07-09 18:15
Director's Dealing
Nykode Therapeutics – Grant of Share Options - Attachment: Attachment 250709.pdf
English 213.3 KB
2025-07-09 18:15
Remuneration Information
Nykode Therapeutics – Grant of Share Options
English 1.1 KB
2025-07-04 16:41
Report Publication Announcement
Financial calendar
English 508 bytes
2025-05-28 07:00
Quarterly Report
Nykode Therapeutics - Quarterly report Q1 2025 - Attachment: 250528 Nykode Quar…
English 4.3 MB
2025-05-28 07:00
Report Publication Announcement
Nykode Therapeutics - Quarterly report Q1 2025
English 3.0 KB
2025-05-27 07:00
Notice of Dividend Amount
Nykode Therapeutics ASA - Ex-dividend NOK 1.00 today
English 490 bytes
2025-05-26 16:51
Report Publication Announcement
Nykode Therapeutics – invitation to Q1 2025 financial results presentation - A…
English 125.5 KB
2025-05-26 16:51
Report Publication Announcement
Nykode Therapeutics – invitation to Q1 2025 financial results presentation
English 3.2 KB
2025-05-26 11:25
Post-Annual General Meeting Information
Nykode Therapeutics ASA - Minutes of Annual General Meeting - Attachment: 25052…
English 297.9 KB

Automate Your Workflow. Get a real-time feed of all Nykode Therapeutics ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Nykode Therapeutics ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.